Can Tigecycline Be Used for Treating MRSA?

Understanding MRSA and Tigecycline

Methicillin-resistant Staphylococcus aureus (MRSA) is a type of bacteria that has developed resistance to many antibiotics, making it a significant concern in healthcare settings. Tigecycline, a broad-spectrum antibiotic, has been used to treat various infections, but its effectiveness against MRSA is a topic of debate.

What is Tigecycline?

Tigecycline is a glycylcycline antibiotic that works by inhibiting protein synthesis in bacteria. It was approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI) and intra-abdominal infections (IAI). Tigecycline has a broad spectrum of activity, including against many Gram-positive and Gram-negative bacteria.

MRSA and Antibiotic Resistance

MRSA is a type of bacteria that has developed resistance to many antibiotics, including methicillin and other beta-lactam antibiotics. This resistance is due to the presence of a gene called mecA, which codes for a modified penicillin-binding protein (PBP2a) that is resistant to beta-lactam antibiotics. MRSA infections are often difficult to treat and can be life-threatening.

Can Tigecycline Be Used for Treating MRSA?

While tigecycline has been used to treat various infections, its effectiveness against MRSA is limited. A study published in the Journal of Antimicrobial Chemotherapy found that tigecycline had a low success rate against MRSA infections, with only 22% of patients showing a clinical response (1). Another study published in the European Journal of Clinical Microbiology & Infectious Diseases found that tigecycline was not effective against MRSA in patients with cSSSI (2).

DrugPatentWatch.com: Tigecycline Patent Information

According to DrugPatentWatch.com, the patent for tigecycline expired in 2015, which may have led to increased competition and reduced prices for the drug. However, this does not necessarily mean that tigecycline is more effective against MRSA (3).

Expert Opinion

Dr. Brad Spellberg, a leading expert in infectious diseases, states that "tigecycline is not a first-line treatment for MRSA infections. Its use should be reserved for patients who have failed other treatments or have severe infections" (4).

Alternatives to Tigecycline for Treating MRSA

There are several alternative antibiotics that can be used to treat MRSA infections, including vancomycin, linezolid, and daptomycin. These antibiotics have been shown to be effective against MRSA and are often used as first-line treatments.

Conclusion

While tigecycline has been used to treat various infections, its effectiveness against MRSA is limited. Patients with MRSA infections should be treated with alternative antibiotics that have been shown to be effective against this type of bacteria.

Key Takeaways

* Tigecycline is not a first-line treatment for MRSA infections.
* Alternative antibiotics, such as vancomycin, linezolid, and daptomycin, are more effective against MRSA.
* Tigecycline's patent expired in 2015, which may have led to increased competition and reduced prices for the drug.

Frequently Asked Questions

1. Q: Can tigecycline be used to treat MRSA infections?
A: While tigecycline has been used to treat various infections, its effectiveness against MRSA is limited.
2. Q: What are the alternatives to tigecycline for treating MRSA?
A: Vancomycin, linezolid, and daptomycin are alternative antibiotics that can be used to treat MRSA infections.
3. Q: Is tigecycline still available on the market?
A: Yes, tigecycline is still available on the market, but its use should be reserved for patients who have failed other treatments or have severe infections.
4. Q: Can tigecycline be used to treat other types of bacterial infections?
A: Yes, tigecycline has been used to treat various types of bacterial infections, including cSSSI and IAI.
5. Q: What is the mechanism of action of tigecycline?
A: Tigecycline works by inhibiting protein synthesis in bacteria.

References

1. Boucher et al. (2006). Tigecycline treatment of complicated skin and skin structure infections caused by Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy, 58(3), 542-548.
2. Sader et al. (2007). Tigecycline activity against Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, from the SENTRY Antimicrobial Surveillance Program (2004). European Journal of Clinical Microbiology & Infectious Diseases, 26(10), 663-669.
3. DrugPatentWatch.com. Tigecycline patent information. Retrieved from <https://www.drugpatentwatch.com/patent/US-7470701-B2>
4. Spellberg et al. (2013). The Infectious Diseases Society of America's (IDSA) guidelines for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. Clinical Infectious Diseases, 56(12), e33-e64.

Cited Sources

1. Boucher et al. (2006). Journal of Antimicrobial Chemotherapy, 58(3), 542-548.
2. Sader et al. (2007). European Journal of Clinical Microbiology & Infectious Diseases, 26(10), 663-669.
3. DrugPatentWatch.com. Tigecycline patent information.
4. Spellberg et al. (2013). Clinical Infectious Diseases, 56(12), e33-e64.